Opus Genetics reported positive Phase 1/2 clinical trial results for its OPGx-BEST1 gene therapy, showing significant visual function improvements and structural retinal recoveries in patients with BEST1-related inherited retinal diseases. This positive data, coupled with regulatory alignment for Phase 3, is a major catalyst for the company, indicating strong potential for a new treatment in a previously underserved market.
Opus Genetics (IRD) announced highly positive three- and six-month data from the low-dose cohort of its Phase 1/2 BIRD-1 trial for OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases. All five participants showed clinically meaningful improvements in visual function, and four displayed structural retinal recoveries, with a favorable safety profile. This strong data, combined with successful alignment with the FDA on Phase 3 endpoints and a significantly larger addressable market than previously estimated, provides a substantial positive catalyst for IRD. The company plans to commence Phase 3 patient dosing in late 2027, indicating a clear path forward for this potentially transformative therapy. For traders, this news suggests significant upside potential for IRD in the short to medium term, driven by the strong clinical data and regulatory progress, though long-term success hinges on Phase 3 outcomes and eventual market adoption.